Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label study of QTX-2101 plus all-trans retinoic acid in newly diagnosed low-risk acute promyelocytic leukemia
2025-524810-28-00Phase 3Authorised
- Sponsor
- Quetzal Therapeutics
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of QTX-2101 in Acute promyelocytic leukaemia (APL), sponsored by Quetzal Therapeutics. Primary endpoints: Pharmacokinetic parameters and Molecular complete remission. Planned start Jul 2026; status: authorised.
02
Drugs
QTX-2101
03
Conditions
Acute promyelocytic leukaemia (APL)
Beyond the preview
Go deeper on 2025-524810-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524810-28-00.